Why the study?
Does tamoxifen increase the risk of thromboembolism in patients with a known predisposition to thrombosis?
Does tamoxifen increase the risk of thromboembolism in patients with a known predisposition to thrombosis?
This case report raises concerns about the safety of tamoxifen in patients with a known predisposition to thrombosis due to its potential paradoxical estrogenic effects.
Answers are grounded in this paper and cite their sources.
May warrant caution with tamoxifen in thrombosis-prone patients; hypothesis-generating and requires confirmation in controlled studies.
To the Editor.— We question the safety of using tamoxifen citrate for patients with a known predisposition to thrombosis. This antiestrogen has been shown to be an effective hormonal agent in metastatic breast cancer, and so far, few serious side effects have been associated with its use. However, deep-vein thrombosis and pulmonary emboli have occurred in patients taking tamoxifen,1-3and it is possible that this could be related to its paradoxical estrogenic effects. Report of a Case.— A 72-year-old woman with metastatic pleural effusion and bone disease from breast cancer showed development of occlusion of the right brachial and ulnar arteries while she was receiving chemotherapy. A successful thromboembolectomy was performed. There was no obvious cardiac cause of embolism. A year later her disease progressed despite changes in chemotherapy. Estrogen receptor status was unknown. Tamoxifen citrate therapy, 10 mg twice daily, was started but was discontinued after a month
No takes yet. Share an insight, caveat, or question.
Alex Hendrick (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: